New NRT gum
This article was originally published in The Tan Sheet
Executive Summary
Gum containing 2 mg nicotine tartrate salt, rather than nicotine polacrilex, yields "faster and better craving relief," researchers announce at Ninth Annual Meeting of the Society for Research on Nicotine & Tobacco. Raymond Niaura, PhD, Brown Medical School, et al., led a randomized, multi-center, open-label study in which 319 participants lit a cigarette of their choice without inhaling and then chewed either GlaxoSmithKline's Nicorette 2 mg or the experimental gum. After 30 minutes, "92% of rapid-release gum chewers had achieved meaningful relief of craving, compared to only 77% of those on Nicorette," researchers note. Study was sponsored by Bayer Consumer Care. JSR, a Maryland firm that develops "novel treatments for tobacco dependence," noted it is working with Biovail on commercialization of this product. NDA submission for new OTC drug is one to two years away, as Phase III placebo-controlled trials still need to be completed...
|
Gum containing 2 mg nicotine tartrate salt, rather than nicotine polacrilex, yields "faster and better craving relief," researchers announce at Ninth Annual Meeting of the Society for Research on Nicotine & Tobacco. Raymond Niaura, PhD, Brown Medical School, et al., led a randomized, multi-center, open-label study in which 319 participants lit a cigarette of their choice without inhaling and then chewed either GlaxoSmithKline's Nicorette 2 mg or the experimental gum. After 30 minutes, "92% of rapid-release gum chewers had achieved meaningful relief of craving, compared to only 77% of those on Nicorette," researchers note. Study was sponsored by Bayer Consumer Care. JSR, a Maryland firm that develops "novel treatments for tobacco dependence," noted it is working with Biovail on commercialization of this product. NDA submission for new OTC drug is one to two years away, as Phase III placebo-controlled trials still need to be completed.... |